收稿日期: 2023-07-11
网络出版日期: 2024-01-10
基金资助
广东省中医药局科研项目(20223033);广州市科技计划项目(202002030174)
Screening of gene differential expression of adenosine deaminase RNA specific 1 in cervical cancer cells based on transcriptome sequencing technology
Received date: 2023-07-11
Online published: 2024-01-10
目的 使用RNA-seq技术分析腺苷脱氨酶1（ADAR1）在宫颈癌Hela细胞株中对基因表达的调控情况，并为揭示ADAR1在宫颈癌发生和进展中的作用提供理论依据。 方法 对正常和ADAR1敲低的Hela细胞株进行RNA-seq测序，筛选出差异表达基因。通过KEGG Pathway、GO cellular和GSEA富集分析，分析ADAR1在Hela细胞株中参与的相关信号通路和生物学过程。 结果 差异表达基因主要富集在免疫和炎症相关信号通路（如TNF-α/NF-κB、NIK/NF-κB、Jak/Stat-IL-6）、Hippo信号通路、TGF-β等信号通路上，参与了干扰素应答、细胞氨基酸代谢调控、蛋白质泛素化/去泛素化、病毒转录等生物过程；对NF-κB信号通路的相关基因进行深入分析后发现，ADAR1敲低后，NF-κB1和TRAF5的mRNA表达水平明显升高（P < 0.05）。 结论 ADAR1可能通过调控NF-κB信号通路相关因子的表达，进而调控宫颈癌的发生和发展。
张华明 , 何婉珊 , 韩芸 , 陈冠桥 , 陈斌 , 韦之富 , 伍恒英 , 文斌 . 基于转录组测序探索腺苷脱氨酶1对宫颈癌细胞的调控机制[J]. 实用医学杂志, 2023 , 39(24) : 3169 -3174 . DOI: 10.3969/j.issn.1006-5725.2023.24.004
Objective To analyze the regulation of gene expression by adenosine deaminase RNA specific 1（ADAR1） in cervical cancer cell line Hela using RNA-seq technology and provide theoretical basis for understanding the role of ADAR1 in the occurrence and progression of cervical cancer. Methods RNA-seq sequencing of normal and ADAR1 knockdown Hela cell lines to identify differentially expressed genes. By conducting enrichment analysis using KEGG Pathway， GO cellular， and GSEA， the study analyzes the relevant signaling pathways and biological processes involving ADAR1 in Hela cell lines. Results Differentially expressed genes are mainly enriched in immune and inflammation-related signaling pathways （such as TNF-α/NF-κB， NIK/NF-κB， Jak/Stat-IL-6）， Hippo signaling pathway， TGF-β signaling pathway， and are involved in interferon response， cellular amino acid metabolism regulation， protein ubiquitination/deubiquitination， viral transcription， and other biological processes. Further analysis of the NF-κB signaling pathway revealed a significant increase in the mRNA expression levels of NF-κB1 and TRAF5 after ADAR1 knockdown. Conclusion ADAR1 may regulate the expression of NF-κB signaling pathway-related factors and thereby regulate the occurrence and development of cervical cancer.
| 1 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021，71（3）：209-249. |
| 2 | SIEGEL R， MILLER K， FUCHS H， et al. Cancer statistics， 2022［J］. CA Cancer J Clin， 2022，72（1）：7-33. |
| 3 | SINGH D， VIGNAT J， LORENZONI V， et al. Global estimates of incidence and mortality of cervical cancer in 2020： a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative［J］. Lancet Glob Health， 2023，11（2）：e197-e206. |
| 4 | SAMUEL C E. Adenosine deaminase acting on RNA （ADAR1）， a suppressor of double-stranded RNA-triggered innate immune responses［J］. J Biol Chem， 2019，294（5）：1710-1720. |
| 5 | ISHIZUKA J J， MANGUSO R T， CHERUIYOT C K， et al. Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade［J］. Nature， 2019，565（7737）：43-48. |
| 6 | KARKI R， SUNDARAM B， SHARMA B， et al. ADAR1 restricts ZBP1-mediated immune response and PANoptosis to promote tumorigenesis［J］. Cell Rep， 2021，37（3）：109858. |
| 7 | HERBERT A. Mendelian disease caused by variants affecting recognition of Z-DNA and Z-RNA by the Zα domain of the double-stranded RNA editing enzyme ADAR［J］. Eur J Hum Genet， 2020，28（1）：114-117. |
| 8 | ZHANG T， YIN C， FEDOROV A， et al. ADAR1 masks the cancer immunotherapeutic promise of ZBP1-driven necroptosis［J］. Nature，2022，606（7914）：594-602. |
| 9 | NAKAMURA K， SHIGEYASU K， OKAMOTO K， et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer［J］. Gynecol Oncol，2022，166（2）：326-333. |
| 10 | 何婉珊，洪小山，陈冠桥，等. 基于转录组测序技术筛选NSUN2在卵巢癌细胞的基因差异表达［J］. 实用医学杂志，2023，39（9）：1079-1085. |
| 11 | NAKAMURA K， SHIGEYASU K， OKAMOTO K， et al. ADAR1 has an oncogenic function and can be a prognostic factor in cervical cancer［J］. Sci Rep， 2023，13（1）：4720. |
| 12 | 雷静静，冯光，唐铖铖，等. 基于RNA-seq筛选NSUN2调控的A549细胞差异表达基因［J］. 陕西理工大学学报（自然科学版），2022，38（2）：58-65. |
| 13 | NICHOLS P， BEVERS S， HENEN M， et al. Recognition of non-CpG repeats in Alu and ribosomal RNAs by the Z-RNA binding domain of ADAR1 induces A-Z junctions［J］. Nat Commun，2021，12（1）：793. |
| 14 | MEHDIPOUR P， MARHON S， ETTAYEBI I， et al. Epigenetic therapy induces transcription of inverted SINEs and ADAR1 dependency［J］. Nature，2020，588（7836）：169-173. |
| 15 | CARTY F， LAYZELL S， BARBARULO A， et al. IKK promotes na?ve T cell survival by repressing RIPK1-dependent apoptosis and activating NF-κB［J］. Sci Signal，2023，16（791）：eabo4094. |
| 16 | LIN X， YOSHIKAWA N， LIU W， et al. DDIT4 Facilitates Lymph Node Metastasis via the Activation of NF-κB Pathway and Epithelial-Mesenchymal Transition［J］. Reprod Sci，2023，30（9）：2829-2841. |
| 17 | HOU S， WANG X， GUO T， et al. PHF6 maintains acute myeloid leukemia via regulating NF-κB signaling pathway［J］. Leukemia，2023，37（8）：1626-1637. |
| 18 | LOW J T， CHRISTIE M， ERNST M， et al. Loss of NFKB1 Results in Expression of Tumor Necrosis Factor and Activation of Signal Transducer and Activator of Transcription 1 to Promote Gastric Tumorigenesis in Mice［J］.Gastroenterology， 2020，159（4）：1444-1458.e15. |
| 19 | WU Y， WANG Q， LI M， et al. SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis［J］. J Clin Invest， 2023，133（6）：e150224. |
| 20 | SUN G， ZHENG C， DENG Z， et al. TRAF5 promotes the occurrence and development of colon cancer via the activation of PI3K/AKT/NF?κB signaling pathways［J］. J Biol Regul Homeost Agents， 2020，34（4）：1257-1268. |
| 21 | LAN H， LIU Y， LIU J， et al. Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m（6）A of TRAF5 and Necroptosis in Colorectal Cancer［J］. Mol Pharm，2021，18（3）：1026-1037. |
/
| 〈 |
|
〉 |